HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy

Blood

Volumn 93, Issue 1, 1999, Pages 370-375

  Bergeron, Raymond J ^a   Wiegand, Jan ^b   Brittenham, Gary M ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE; IRON CHELATE; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; SODIUM DIHYDROGEN PHOSPHATE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DOSE CALCULATION; DRUG STRUCTURE; IRON CHELATION; IRON TRANSPORT; MALE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIMATE; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032908391     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.1.370.401k29_370_375     Document Type: Article

References (38)

1. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331:574, 1994
2. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 331:567, 1994
3. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 89:739, 1997
4. Bickel H, Hall GE, Keller-Schierlein W, Prelog V, Vischer E, Wettstein A: Metabolic products of actinomycetes. XXVII. Constitutional formula of ferrioxamine B. Helv Chim Acta 43:2129, 1960
5. Weatherall DJ: The treatment of thalassemia - Slow progress and new dilemmas. N Engl J Med 329:877, 1993
6. Cao A, Galanello R, Rosatelli MC, Argiolu F, De Virgiliis S: Clinical experience of management of thalassemia: The Sardinian experience. Semin Hematol 33:66, 1996
7. Gabutti V, Piga A: Results of long-term iron-chelating therapy. Acta Haematol 95:26, 1996
8. Giardina PJ, Grady RW: Chelation therapy in beta-thalassemia: The benefits and limitations of desferrioxamine. Semin Hematol 32:304, 1995
9. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG: Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 312:1600, 1985
10. Pippard MJ, Callender ST, Finch CA: Ferrioxamine excretion in iron-loaded man. Blood 60:288, 1982
11. Pippard MJ: Desferrioxamine-induced iron excretion in humans. Baillieres Clin Haematol 2:323, 1989
12. Lee P, Mohammed N, Marshall L, Abeysinghe RD, Hider RC, Porter JB, Singh S: Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos 21:640, 1993
13. DeVirgilis S, Congia M, Frau F, Argiolu F, Cucca F, Varsi A, Sanna G, Podda G, Fodde M, Franco-Piratu G, Cao A: Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 113:661, 1998
14. Olivieri NF, Buncic R, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B, Taylor M, Freedman MH: Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 314:869, 1986
15. Porter JB, Jawson MS, Huehns ER, East CA, Hazell JWP: Deferoxamine ototoxicity: Evaluation of risk factors in thalassemic patients and guidelines for safe dosage. Br J Haematol 73:403, 1989
16. Porter J, Huehns E: The toxic effects of desferrioxamine. Baillieres Clin Hematol 2:459, 1989
17. Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF: The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Hematol 54:371, 1992
18. Tenenbein M, Kowalski S, Sienko A, Bowden DH, Adamson IYR: Pulmonary toxic effects of continuous deferoxamine administration in acute iron poisoning. Lancet 339:699, 1992
19. Brill PW, Winchester P, Giardina PJ, Cunningham-Rundles S: Desferrioxamine-induced bone dysplasia in patients with thalassemia major. Am J Roentgenol 156:561, 1991
20. Porter JB: Evaluation of new iron chelators for clinical use. Acta Haematol 95:13, 1996
21. Brittenham GM: Development of iron-chelating agents for clinical use. Blood 80:569, 1992
22. L'Eplattenier F, Murase I, Martell AE: New multidentate ligands. VI. Chelating tendencies of N,N′-di(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid. J Am Chem Soc 89:837, 1967
23. Athanasiou A, Shep MA, Necheles TF: Anaphylactic reaction to desferrioxamine. Lancet 2:616, 1981
24. Miller KB, Rosenwasser LJ, Bessette JAM, Beer DJ, Rocklin RE: Rapid desensitization for desferrioxamine anaphylactic reactions. Lancet 1:1059, 1981
25. Shalit M, Tedeschi A, Miadonna A, Levi-Schaffer F: Desferal (desferrioxamine) - A novel activator of tissue-type mast cells. J Allergy Clin Immunol 88:854, 1991
26. Bergeron RJ, Wiegand J, Brittenham GM: HBED: Potential alternative to deferoxamine for iron-chelating therapy. Blood 91:1446, 1998
27. Bergeron RJ, Streiff RR, Creary EA, Daniels RD Jr, King W, Luchetta G, Wiegand J, Moerker T, Peter HH: A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood 81:2166, 1993
28. Bergeron RJ, Streiff RR, Wiegand J, Luchetta G, Creary EA, Peter HH: A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 79:1882, 1992
29. Wood JK, Milner PF, Pathak UN: The metabolism of iron-dextran given as a total-dose infusion to iron deficient Jamaican subjects. Br J Haematol 14:119, 1968
30. Bergeron RJ, Streiff RR, Wiegand J, Vinson JR, Luchetta G, Evans KM, Peter H, Jenny HB: A comparative evaluation of iron clearance models. Ann NY Acad Sci 612:378, 1990
31. Peter HH, Bergeron RJ, Streiff RR, Wiegand J: A comparative evaluation of iron chelators in a primate model, in Bergeron RJ, Brittenham GM (eds): The Development of Iron Chelators for Clinical Use. Boca Raton, FL, CRC Press, 1994, p 373
32. Grady RW, Hershko C: HBED: A potential oral iron chelator. Ann NY Acad Sci 612:361, 1990
33. Hershko C, Grady RW, Link G: Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters. Haematologia (Budap) 17:25, 1984
34. Hershko C, Grady RW, Link G: Phenolic ethylenediamine derivatives: A study of orally effective iron chelators. J Lab Clin Med 103:337, 1984
35. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ: Preliminary results from a Phase I clinical trial of HBED, in Bergeron RJ, Brittenham GM (eds): The Development of Iron Chelators for Clinical Use. Boca Raton, FL, CRC Press, 1994, p 395
36. Grady RW, Salbe AD, Hilgartner MW, Giardina PJ: Results from a phase I clinical trial of HBED. Adv Exp Med Biol 356:351, 1994
37. Brittenham GM: Pyridoxal isonicotinoyl hydrazone: An effective chelator after oral administration. Semin Hematol 27:112, 1990
38. Bergeron R, Streiff RR, King W, Daniels RD Jr, Wiegand J: A comparison of the iron-clearing properties of parabactin and desferrioxamine. Blood 82:2552, 1993